查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1572061

阿加曲班市場：依產品類型、應用、最終用戶、治療領域、給藥途徑- 2025-2030 年全球預測

Argatroban Market by Product Type (Dosage Strength, Formulations), Application (Percutaneous Coronary Intervention, Treatment Of Heparin-Induced Thrombocytopenia), End-User, Therapeutic Area, Route Of Administration - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年阿加曲班市值為6,468萬美元，預計2024年將達6,734萬美元，預計2030年將達到8,567萬美元，複合年成長率為4.09%。

阿加曲班是一種小分子直接凝血酶抑制劑，主要用於抗凝血治療，特別是肝素誘發的血小板減少性疾病(HIT) 和需要經皮冠狀動脈介入治療的患者。當肝素等傳統抗凝血劑無法安全使用時，該藥物在預防血栓併發症發揮重要作用，因此需要該藥物。其在醫學上的應用範圍很廣泛，延伸到心血管治療和急診環境，其中準確的抗凝血管理非常重要。最終用途部分主要是醫院、急診服務和專科診所，門診病人設施的興趣也越來越大。

主要市場統計
基準年[2023] 6468萬美元
預測年份 [2024] 6734萬美元
預測年份 [2030] 8567萬美元
複合年成長率（%） 4.09%

阿加曲班的市場成長是由於心血管疾病盛行率的增加、抗凝血治療意識的提高以及在醫療基礎設施發達的新興市場擴大應用所推動的。另一個重要因素是它在接受透析的患者中的使用，當傳統抗凝血劑構成高風險時，提供了一種替代方案。最近的趨勢是透過患者教育和健康專業培訓計劃擴大該藥物在新興市場的採用。與醫療保健提供者合作提高阿加曲班在 HIT 管理中的有效性可以擴大其市場範圍。

然而，高成本、嚴格的監管要求和潛在副作用等限制限制了更廣泛的採用。此外，來自較成熟的抗凝血劑（例如新型口服抗凝血劑（NOAC））的競爭也是一個挑戰。透過具有成本效益的製造流程和明確的監管規定來解決這些因素可以加速市場進入和成長。

創新和研發可以在標靶給藥系統的開發中蓬勃發展，從而提高阿加曲班的功效和安全性。數位健康工具的出現可以支持個人化治療方法、最佳化劑量並減少副作用。總體而言，與製藥創新者和技術公司的策略夥伴關係可以為提高阿加曲班的市場地位開闢新途徑。儘管市場競爭激烈，但由於持續的研究和開發專注於改善治療結果和減少不利事件以滿足未滿足的臨床需求，因此它是一個充滿前景的市場。

市場動態：揭示快速發展的阿加曲班市場的關鍵市場洞察

阿加曲班市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 抗凝血劑配方和輸送系統的進步提高了阿加曲班的療效和病人依從性
    • 增加醫療基礎設施和抗凝血研究投資，支持阿加曲班市場擴張
    • 對血栓性栓塞症的認知和診斷的提高有助於阿加曲班的市場滲透
    • 主要企業之間的策略夥伴關係和聯盟推動阿加曲班市場動態
  • 市場限制因素
    • 阿加曲班的初始成本較高，限制了其在成本敏感市場的可用性；
    • 其他抗凝血劑和新興治療方法的競爭
  • 市場機會
    • 由於心血管疾病的增加，對抗凝血治療的需求不斷增加
    • 加大新型抗凝血劑研發投入
    • 新興國家阿加曲班市場的拓展重點關注醫療改善
  • 市場問題
    • 影響阿加曲班生產過程的原料供應限制和供應鏈中斷
    • 嚴格的監管核准和合規要求阻礙了阿加曲班產品創新和市場進入

波特五力：駕馭阿加曲班市場的策略工具

波特的五力架構是了解阿加曲班市場競爭格局的關鍵工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，確保更強大的市場地位。

PESTLE分析：了解阿加曲班市場的外部影響

外部宏觀環境因素在塑造阿加曲班市場的業績動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解阿加曲班市場的競爭狀況

對阿加曲班市場的詳細市場佔有率分析可以對供應商的業績進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來發現自己的競爭定位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，以應對日益激烈的競爭。

FPNV 定位矩陣阿加曲班市場供應商的績效評估

FPNV定位矩陣是評估Argatroban市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃阿加曲班市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，阿加曲班市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭格局中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 抗凝血劑配方和輸送系統的進步提高了阿加曲班的療效和病人的依從性
      • 增加醫療基礎設施和抗凝血研究投資，推動阿加曲班市場擴張
      • 提高對血栓栓塞性疾病的認知和診斷有助於提高阿加曲班市場滲透率
      • 推動阿加曲班市場動態的主要企業之間的策略夥伴關係和合作
    • 抑制因素
      • 阿加曲班的高初始成本限制了成本敏感市場的可用性
      • 其他抗凝血劑和新治療方法的競爭
    • 機會
      • 由於心血管疾病的增加，抗凝血治療的需求增加
      • 加大新型抗凝血劑研發投入
      • 以醫療改善為中心拓展新興國家阿加曲班市場
    • 任務
      • 原料供應和供應鏈中斷影響阿加曲班生產過程
      • 嚴格的監管核准和合規要求阻礙了阿加曲班產品創新和市場進入
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章阿加曲班市場：依產品類型

  • 介紹
  • 劑量強度
    • 1mg/mL
    • 2mg/mL
  • 處方
    • 注射液
    • 溶液用粉末

第7章阿加曲班市場：依應用分類

  • 介紹
  • 經皮冠狀動脈介入治療
    • 治療中
    • 術後護理
  • 肝素誘發的血小板減少性疾病的治療
    • 急性病例
    • 慢性病例

第8章阿加曲班市場：依最終用戶分類

  • 介紹
  • 門診手術中心
    • 醫院相關中心
    • 獨立中心
  • 診所
    • 普通科診所
    • 專科診所
  • 醫院
    • 私立醫院
    • 公立醫院

第9章阿加曲班市場：依治療領域

  • 介紹
  • 心臟病學
    • 入侵性心臟病學
    • 無創心臟病學
  • 加護治療
    • 緊急護理
    • 加護治療
  • 血液學
    • 血液疾病
    • 凝血病

第 10 章 阿加曲班市場：依給藥途徑

  • 介紹
  • 心內給藥
  • 靜脈注射

第11章 美洲阿加曲班市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太阿加曲班市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章 歐洲、中東和非洲阿加曲班市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • 1. Abbvie Inc.
  • 2. AstraZeneca Plc
  • 3. Bayer AG
  • 4. Boehringer Ingelheim GmbH
  • 5. Bristol-Myers Squibb Company
  • 6. Cipla Limited
  • 7. Dr. Reddy's Laboratories Ltd.
  • 8. Eagle Pharmaceuticals Inc.
  • 9. Fresenius Kabi AG
  • 10. GlaxoSmithKline plc (GSK)
  • 11. Hoffmann-La Roche Ltd.
  • 12. Johnson & Johnson
  • 13. Merck & Co., Inc.
  • 14. Mitsubishi Tanabe Pharma Corporation
  • 15. Mylan NV
  • 16. Pfizer Inc.
  • 17. Sandoz (a Novartis Division)
  • 18. Sanofi SA
  • 19. Sun Pharmaceutical Industries Ltd.
  • 20. Teva Pharmaceutical Industries Ltd.
Product Code: MRR-535C62918B41

The Argatroban Market was valued at USD 64.68 million in 2023, expected to reach USD 67.34 million in 2024, and is projected to grow at a CAGR of 4.09%, to USD 85.67 million by 2030.

Argatroban, a small molecule direct thrombin inhibitor, is primarily used for anticoagulation therapy, particularly in patients with heparin-induced thrombocytopenia (HIT) and those requiring percutaneous coronary intervention. The drug's necessity is underscored by its critical role in preventing thrombotic complications where traditional anticoagulants like heparin cannot be used safely. The application scope is wide-ranging within healthcare, extending into cardiovascular treatment and acute care settings, where precise anticoagulation management is crucial. End-use sectors are mainly hospitals, emergency services, and specialty clinics, with a growing interest from outpatient facilities as well.

KEY MARKET STATISTICS
Base Year [2023] USD 64.68 million
Estimated Year [2024] USD 67.34 million
Forecast Year [2030] USD 85.67 million
CAGR (%) 4.09%

Market growth for argatroban is being driven by an increasing incidence of cardiovascular diseases, heightened awareness regarding anticoagulation therapy, and an expansion of its application in emerging markets with improving healthcare infrastructure. Another key factor is its use in patients undergoing dialysis, providing an alternative where traditional anticoagulants pose higher risks. Recent opportunities revolve around expanding the drug's adoption in developing markets through patient education and healthcare professional training programs. Collaborations with healthcare providers to increase the efficacy of argatroban in HIT management could broaden its market scope.

However, limitations such as high cost, stringent regulatory requirements, and the potential for adverse reactions restrict broader adoption. Additionally, competition from more established anticoagulants, such as newer oral anticoagulants (NOACs), poses challenges. Addressing these factors through cost-effective manufacturing processes and clearer regulatory pathways can accelerate market entry and growth.

Innovation and research could thrive in developing targeted drug delivery systems that increase argatroban's efficacy and safety profile. The advent of digital health tools can support personalized treatment approaches, optimizing dosing and reducing adverse reactions. Overall, strategic partnerships with pharmaceutical innovators and technology companies may open new avenues for advancing argatroban's market position. The market nature is competitive yet promising, as ongoing research and development focus on enhancing therapeutic outcomes and reducing adverse events to capitalize on unmet clinical needs.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Argatroban Market

The Argatroban Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Advancements in anticoagulant formulations and delivery systems improving argatroban efficacy and patient compliance
    • Increasing investment in healthcare infrastructure and anticoagulant research propelling argatroban market expansion
    • Growing awareness and diagnosis of thromboembolic disorders contributing to higher argatroban market penetration
    • Strategic partnerships and collaborations among key players driving argatroban market dynamics
  • Market Restraints
    • High initial cost of argatroban, limiting its accessibility in cost-sensitive markets
    • Competition among other anticoagulants and emerging therapies
  • Market Opportunities
    • Growing demand for anticoagulant therapies due to rise in cardiovascular diseases
    • Increasing investments in research and development for novel anticoagulant drugs
    • Expansion of the argatroban market in emerging economies with a focus on healthcare improvement
  • Market Challenges
    • Limited availability of raw materials and supply chain disruptions affecting argatroban production processes
    • Stringent regulatory approvals and compliance requirements hindering the innovation and market entry of argatroban products

Porter's Five Forces: A Strategic Tool for Navigating the Argatroban Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Argatroban Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Argatroban Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Argatroban Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Argatroban Market

A detailed market share analysis in the Argatroban Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Argatroban Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Argatroban Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Argatroban Market

A strategic analysis of the Argatroban Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Argatroban Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Limited, Dr. Reddy's Laboratories Ltd., Eagle Pharmaceuticals Inc., Fresenius Kabi AG, GlaxoSmithKline plc (GSK), Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Mylan N.V., Pfizer Inc., Sandoz (a Novartis Division), Sanofi S.A., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Argatroban Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Dosage Strength and Formulations. The Dosage Strength is further studied across 1 mg/mL and 2 mg/mL. The Formulations is further studied across Injectable Solutions and Powder For Solution.
  • Based on Application, market is studied across Percutaneous Coronary Intervention and Treatment Of Heparin-Induced Thrombocytopenia. The Percutaneous Coronary Intervention is further studied across During Procedure and Post-Procedure Care. The Treatment Of Heparin-Induced Thrombocytopenia is further studied across Acute Cases and Chronic Cases.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Clinics, and Hospitals. The Ambulatory Surgical Centers is further studied across Hospital-Associated Centers and Standalone Centers. The Clinics is further studied across General Clinics and Specialized Clinics. The Hospitals is further studied across Private Hospitals and Public Hospitals.
  • Based on Therapeutic Area, market is studied across Cardiology, Critical Care, and Hematology. The Cardiology is further studied across Invasive Cardiology and Non-Invasive Cardiology. The Critical Care is further studied across Emergency Care and Intensive Care. The Hematology is further studied across Blood Disorders and Coagulopathies.
  • Based on Route Of Administration, market is studied across Intracardiac Administration and Intravenous Administration.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Advancements in anticoagulant formulations and delivery systems improving argatroban efficacy and patient compliance
      • 5.1.1.2. Increasing investment in healthcare infrastructure and anticoagulant research propelling argatroban market expansion
      • 5.1.1.3. Growing awareness and diagnosis of thromboembolic disorders contributing to higher argatroban market penetration
      • 5.1.1.4. Strategic partnerships and collaborations among key players driving argatroban market dynamics
    • 5.1.2. Restraints
      • 5.1.2.1. High initial cost of argatroban, limiting its accessibility in cost-sensitive markets
      • 5.1.2.2. Competition among other anticoagulants and emerging therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing demand for anticoagulant therapies due to rise in cardiovascular diseases
      • 5.1.3.2. Increasing investments in research and development for novel anticoagulant drugs
      • 5.1.3.3. Expansion of the argatroban market in emerging economies with a focus on healthcare improvement
    • 5.1.4. Challenges
      • 5.1.4.1. Limited availability of raw materials and supply chain disruptions affecting argatroban production processes
      • 5.1.4.2. Stringent regulatory approvals and compliance requirements hindering the innovation and market entry of argatroban products
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Argatroban Market, by Product Type

  • 6.1. Introduction
  • 6.2. Dosage Strength
    • 6.2.1. 1 mg/mL
    • 6.2.2. 2 mg/mL
  • 6.3. Formulations
    • 6.3.1. Injectable Solutions
    • 6.3.2. Powder For Solution

7. Argatroban Market, by Application

  • 7.1. Introduction
  • 7.2. Percutaneous Coronary Intervention
    • 7.2.1. During Procedure
    • 7.2.2. Post-Procedure Care
  • 7.3. Treatment Of Heparin-Induced Thrombocytopenia
    • 7.3.1. Acute Cases
    • 7.3.2. Chronic Cases

8. Argatroban Market, by End-User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
    • 8.2.1. Hospital-Associated Centers
    • 8.2.2. Standalone Centers
  • 8.3. Clinics
    • 8.3.1. General Clinics
    • 8.3.2. Specialized Clinics
  • 8.4. Hospitals
    • 8.4.1. Private Hospitals
    • 8.4.2. Public Hospitals

9. Argatroban Market, by Therapeutic Area

  • 9.1. Introduction
  • 9.2. Cardiology
    • 9.2.1. Invasive Cardiology
    • 9.2.2. Non-Invasive Cardiology
  • 9.3. Critical Care
    • 9.3.1. Emergency Care
    • 9.3.2. Intensive Care
  • 9.4. Hematology
    • 9.4.1. Blood Disorders
    • 9.4.2. Coagulopathies

10. Argatroban Market, by Route Of Administration

  • 10.1. Introduction
  • 10.2. Intracardiac Administration
  • 10.3. Intravenous Administration

11. Americas Argatroban Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Argatroban Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Argatroban Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbvie Inc.
  • 2. AstraZeneca Plc
  • 3. Bayer AG
  • 4. Boehringer Ingelheim GmbH
  • 5. Bristol-Myers Squibb Company
  • 6. Cipla Limited
  • 7. Dr. Reddy's Laboratories Ltd.
  • 8. Eagle Pharmaceuticals Inc.
  • 9. Fresenius Kabi AG
  • 10. GlaxoSmithKline plc (GSK)
  • 11. Hoffmann-La Roche Ltd.
  • 12. Johnson & Johnson
  • 13. Merck & Co., Inc.
  • 14. Mitsubishi Tanabe Pharma Corporation
  • 15. Mylan N.V.
  • 16. Pfizer Inc.
  • 17. Sandoz (a Novartis Division)
  • 18. Sanofi S.A.
  • 19. Sun Pharmaceutical Industries Ltd.
  • 20. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. ARGATROBAN MARKET RESEARCH PROCESS
  • FIGURE 2. ARGATROBAN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ARGATROBAN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ARGATROBAN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ARGATROBAN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ARGATROBAN MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ARGATROBAN MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ARGATROBAN MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ARGATROBAN MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ARGATROBAN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS ARGATROBAN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ARGATROBAN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES ARGATROBAN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ARGATROBAN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. ARGATROBAN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ARGATROBAN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ARGATROBAN MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ARGATROBAN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ARGATROBAN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ARGATROBAN MARKET DYNAMICS
  • TABLE 7. GLOBAL ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ARGATROBAN MARKET SIZE, BY 1 MG/ML, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ARGATROBAN MARKET SIZE, BY 2 MG/ML, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ARGATROBAN MARKET SIZE, BY FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ARGATROBAN MARKET SIZE, BY INJECTABLE SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ARGATROBAN MARKET SIZE, BY POWDER FOR SOLUTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ARGATROBAN MARKET SIZE, BY DURING PROCEDURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ARGATROBAN MARKET SIZE, BY POST-PROCEDURE CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ARGATROBAN MARKET SIZE, BY ACUTE CASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ARGATROBAN MARKET SIZE, BY CHRONIC CASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ARGATROBAN MARKET SIZE, BY HOSPITAL-ASSOCIATED CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ARGATROBAN MARKET SIZE, BY STANDALONE CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ARGATROBAN MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ARGATROBAN MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ARGATROBAN MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ARGATROBAN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ARGATROBAN MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ARGATROBAN MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ARGATROBAN MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ARGATROBAN MARKET SIZE, BY INVASIVE CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ARGATROBAN MARKET SIZE, BY NON-INVASIVE CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ARGATROBAN MARKET SIZE, BY CRITICAL CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ARGATROBAN MARKET SIZE, BY EMERGENCY CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ARGATROBAN MARKET SIZE, BY INTENSIVE CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ARGATROBAN MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ARGATROBAN MARKET SIZE, BY BLOOD DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL ARGATROBAN MARKET SIZE, BY COAGULOPATHIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL ARGATROBAN MARKET SIZE, BY INTRACARDIAC ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL ARGATROBAN MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. AMERICAS ARGATROBAN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 80. ARGENTINA ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 81. ARGENTINA ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82. ARGENTINA ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 83. ARGENTINA ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. ARGENTINA ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 91. BRAZIL ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. BRAZIL ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 93. BRAZIL ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 94. BRAZIL ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 95. BRAZIL ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 96. BRAZIL ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 97. BRAZIL ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 98. BRAZIL ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. BRAZIL ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 102. CANADA ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 103. CANADA ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. CANADA ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 105. CANADA ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 106. CANADA ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. CANADA ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 108. CANADA ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 109. CANADA ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 110. CANADA ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 111. CANADA ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 112. CANADA ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 113. CANADA ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 114. CANADA ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. MEXICO ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. MEXICO ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 117. MEXICO ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 118. MEXICO ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. MEXICO ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 120. MEXICO ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 121. MEXICO ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. MEXICO ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 123. MEXICO ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 124. MEXICO ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 125. MEXICO ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 126. MEXICO ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 127. MEXICO ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 128. MEXICO ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 129. MEXICO ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. UNITED STATES ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. UNITED STATES ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 132. UNITED STATES ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 133. UNITED STATES ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. UNITED STATES ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 135. UNITED STATES ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 136. UNITED STATES ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED STATES ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED STATES ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED STATES ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED STATES ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED STATES ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED STATES ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED STATES ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED STATES ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED STATES ARGATROBAN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 162. AUSTRALIA ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. AUSTRALIA ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 164. AUSTRALIA ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 165. AUSTRALIA ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. AUSTRALIA ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 167. AUSTRALIA ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 168. AUSTRALIA ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. AUSTRALIA ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 170. AUSTRALIA ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 171. AUSTRALIA ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 172. AUSTRALIA ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 173. AUSTRALIA ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 174. AUSTRALIA ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 175. AUSTRALIA ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 176. AUSTRALIA ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. CHINA ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. CHINA ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 179. CHINA ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 180. CHINA ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. CHINA ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 182. CHINA ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 183. CHINA ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. CHINA ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 185. CHINA ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 186. CHINA ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 187. CHINA ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 188. CHINA ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 189. CHINA ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 190. CHINA ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 191. CHINA ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. INDIA ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. INDIA ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 194. INDIA ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 195. INDIA ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 196. INDIA ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 197. INDIA ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 198. INDIA ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 199. INDIA ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 200. INDIA ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 201. INDIA ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 202. INDIA ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 203. INDIA ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 204. INDIA ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 205. INDIA ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 206. INDIA ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 207. INDONESIA ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. INDONESIA ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 209. INDONESIA ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 210. INDONESIA ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 211. INDONESIA ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 212. INDONESIA ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 213. INDONESIA ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 214. INDONESIA ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 215. INDONESIA ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 216. INDONESIA ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 217. INDONESIA ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 218. INDONESIA ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 219. INDONESIA ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 220. INDONESIA ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 221. INDONESIA ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 222. JAPAN ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. JAPAN ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 224. JAPAN ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 225. JAPAN ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 226. JAPAN ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 227. JAPAN ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 228. JAPAN ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 229. JAPAN ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 230. JAPAN ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 231. JAPAN ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 232. JAPAN ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 233. JAPAN ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 234. JAPAN ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 235. JAPAN ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 236. JAPAN ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 237. MALAYSIA ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. MALAYSIA ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 239. MALAYSIA ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 240. MALAYSIA ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 241. MALAYSIA ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 242. MALAYSIA ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 243. MALAYSIA ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 244. MALAYSIA ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 245. MALAYSIA ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 246. MALAYSIA ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 247. MALAYSIA ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 248. MALAYSIA ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 249. MALAYSIA ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 250. MALAYSIA ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 251. MALAYSIA ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 252. PHILIPPINES ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. PHILIPPINES ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 254. PHILIPPINES ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 255. PHILIPPINES ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 256. PHILIPPINES ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 257. PHILIPPINES ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 258. PHILIPPINES ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 259. PHILIPPINES ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 260. PHILIPPINES ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 261. PHILIPPINES ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 262. PHILIPPINES ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 263. PHILIPPINES ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 264. PHILIPPINES ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 265. PHILIPPINES ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 266. PHILIPPINES ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 267. SINGAPORE ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. SINGAPORE ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 269. SINGAPORE ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 270. SINGAPORE ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 271. SINGAPORE ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 272. SINGAPORE ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 273. SINGAPORE ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 274. SINGAPORE ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 275. SINGAPORE ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 276. SINGAPORE ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 277. SINGAPORE ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 278. SINGAPORE ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 279. SINGAPORE ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 280. SINGAPORE ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 281. SINGAPORE ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH KOREA ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH KOREA ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 284. SOUTH KOREA ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 285. SOUTH KOREA ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 286. SOUTH KOREA ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 287. SOUTH KOREA ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 288. SOUTH KOREA ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 289. SOUTH KOREA ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 290. SOUTH KOREA ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 291. SOUTH KOREA ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 292. SOUTH KOREA ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 293. SOUTH KOREA ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 294. SOUTH KOREA ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 295. SOUTH KOREA ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 296. SOUTH KOREA ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 297. TAIWAN ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. TAIWAN ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 299. TAIWAN ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 300. TAIWAN ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 301. TAIWAN ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 302. TAIWAN ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 303. TAIWAN ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 304. TAIWAN ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 305. TAIWAN ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 306. TAIWAN ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 307. TAIWAN ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 308. TAIWAN ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 309. TAIWAN ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 310. TAIWAN ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 311. TAIWAN ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 312. THAILAND ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 313. THAILAND ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 314. THAILAND ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 315. THAILAND ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 316. THAILAND ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 317. THAILAND ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 318. THAILAND ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 319. THAILAND ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 320. THAILAND ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 321. THAILAND ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 322. THAILAND ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 323. THAILAND ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 324. THAILAND ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 325. THAILAND ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 326. THAILAND ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 327. VIETNAM ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 328. VIETNAM ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 329. VIETNAM ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 330. VIETNAM ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 331. VIETNAM ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 332. VIETNAM ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 333. VIETNAM ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 334. VIETNAM ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 335. VIETNAM ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 336. VIETNAM ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 337. VIETNAM ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 338. VIETNAM ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 339. VIETNAM ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 340. VIETNAM ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 341. VIETNAM ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 342. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 343. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 344. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 345. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 346. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 347. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
  • TABLE 348. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 349. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
  • TABLE 350. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 351. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 352. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 353. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 354. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
  • TABLE 355. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 356. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 357. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 358. DENMARK ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 359. DENMARK ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 360. DENMARK ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 361. DENMARK ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 362. DENMARK ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONA